Search

Displaying results 971 - 980 of 7058 in total
  1. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    [FDA Label]. … Ecallantide is a recombinant 60-amino-acid protein produced in _Pichia pastoris_ yeast cells that contains three intramolecular disulfide bonds [FDA Label].

  2. Drug

    Prochlorperazine

    go.drugbank.com/drugs/DB00433
    ApprovedInvestigationalVet approved

    [L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. … [label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.

    Categories: Dopamine D2 Receptor Antagonists
  3. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

    Mixtures: DM Syrup, DONEXAN DX
  4. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. … [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977.

    Products: LORAZEPAM DOC GENERICI, LORAZEPAM MYLAN GENERICS
  5. Drug

    Coral snake (micrurus fulvius) immune globulin antivenin (equine)

    go.drugbank.com/drugs/DB13883
    Approved

    fulvius fulvius) venom [FDA Label]. … Prior to lyophilization, the product contains 0.25% phenol and 0.005% thiomerosal (mercury derivative) [FDA Label].

  6. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

  7. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081]. … It is widely used as a sugar substitute and in "sugar-free" food products.

    Mixtures: Fluor-a-day, Fluor-a-dayCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Sevasemten

    go.drugbank.com/drugs/DB18983
    Investigational

    Sevasemten is under investigation in clinical trial NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)).

  9. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine is an opioid receptor antagonist [FDA Label]. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  10. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28].